Edap Tms S.A. (NASDAQ:EDAP) Short Interest Update

Key Points

• Short interest fell 32.3% in April to 37,921 shares (about 0.1% of shares outstanding), with a days-to-cover ratio of 1.5, suggesting relatively low short-selling pressure.
• Analyst sentiment is mixed: the stock has an average rating of Hold and a consensus price target of $6.00, though firms have issued divergent views (HC Wainwright still a Buy but cut its target to $10, while others moved to Hold/Sell).
• Recent fundamentals show a Q1 EPS miss (loss of $0.25 vs. $0.16 expected) with negative net margin and return on equity, while EDAP shares trade around $3.28 with a market cap of roughly $123 million and a 52-week range of $1.21–$5.05.

Edap Tms S.A. (NASDAQ:EDAP - Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 37,921 shares, a decrease of 32.3% from the March 31st total of 56,032 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 25,459 shares, the days-to-cover ratio is currently 1.5 days.

Analyst Upgrades and Downgrades

Several research analysts have commented on EDAP shares. Wall Street Zen cut shares of Edap Tms from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Edap Tms in a research note on Monday, December 29th. Finally, HC Wainwright dropped their price target on shares of Edap Tms from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, April 9th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $6.00.

Institutional Investors Weigh In On Edap Tms

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EDAP. Flax Pond Capital LLC bought a new position in Edap Tms during the 4th quarter valued at $2,623,000. Leonteq Securities AG bought a new stake in shares of Edap Tms in the 4th quarter worth $313,000. Rock Springs Capital Management LP raised its stake in shares of Edap Tms by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock worth $4,233,000 after buying an additional 16,500 shares in the last quarter. Kovack Advisors Inc. acquired a new stake in shares of Edap Tms in the fourth quarter valued at $53,000. Finally, SmartHarvest Portfolios LLC bought a new position in Edap Tms during the first quarter valued at about $38,000. Institutional investors own 62.74% of the company's stock.

Edap Tms Price Performance

EDAP stock traded up $0.06 during trading on Tuesday, hitting $3.28. The company had a trading volume of 36,276 shares, compared to its average volume of 58,521. The business has a 50 day moving average of $3.82 and a 200 day moving average of $3.32. The firm has a market capitalization of $122.94 million, a price-to-earnings ratio of -4.26 and a beta of -0.09. The company has a current ratio of 1.54, a quick ratio of 1.19 and a debt-to-equity ratio of 0.84. Edap Tms has a fifty-two week low of $1.21 and a fifty-two week high of $5.05.

Edap Tms (NASDAQ:EDAP - Get Free Report) last released its earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Edap Tms had a negative net margin of 41.24% and a negative return on equity of 100.07%. The company had revenue of $22.22 million for the quarter, compared to analyst estimates of $21.28 million. As a group, research analysts predict that Edap Tms will post -0.79 earnings per share for the current year.

Edap Tms Company Profile

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.